LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.91m
- $0.22m
- $0.17m
Lisata Therapeutics up on EMA orphan tag for cancer drug candidate
Brief: Lisata Therapeutics Announces First Patient Treated In Bolster Trial Of Lsta1, A Novel Tumor-Targeting And Penetrating Peptide, In Patients With Advanced Solid Tumors
Brief: Lisata Therapeutics Announces Outcome Of Interim Futility Analysis For Its Phase 2B Trial Of LSTA1 In Metastatic Pancreatic Ductal Adenocarcinoma
Brief: Lisata Therapeutics Q2 EPS USD -0.5
Lisata Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Lisata Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Amgen, New York Times, Jacobs Solutions
U.S. STOCKS ON THE MOVE-Organon, Bio-Techne, TransDigm
U.S. STOCKS ON THE MOVE-DISH Network, Lisata Therapeutics, WeightWatchers
Brief: Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To LSTA1 For The Treatment Of Malignant Glioma
Lisata Therapeutics up as FDA grants orphan drug tag to cancer drug candidate
Lisata Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: Lisata Therapeutics Announces Enhancements To Ongoing Phase 2B Ascend Trial Of LSTA1
Lisata Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Lisata Therapeutics Reports First Quarter 2023 Financial Results And Provides Business Update
Lisata Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Lisata Therapeutics Says On May 1, Eliminated Position Of President & Chief Business Officer
Lisata Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Lisata Therapeutics Receives $2.2 Million Of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program